NEW YORK--(BUSINESS WIRE)--Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced that Merck, known as MSD outside of the United States and Canada, has joined its Data Syndication Partnership program for the LEARNS observational study, which seeks to develop digital biomarkers in neurodegenerative disorders from smart phone-based assessments and wearable technologies.

纽约--（商业新闻短讯）--医疗保健技术公司Koneksa是一家开创循证数字生物标志物的公司，宣布默克公司（在美国和加拿大以外被称为MSD）已加入其数据联合伙伴关系计划，用于LEARNS观察性研究，该研究旨在通过基于智能手机的评估和可穿戴技术开发神经退行性疾病的数字生物标志物。

As a member, Merck researchers will have real-time access to data and results from the ongoing study..

作为成员，默克研究人员将实时访问正在进行的研究的数据和结果。。

“The healthcare community urgently needs better well-validated measures of Parkinson’s disease progression to inform drug development,” said Chris Benko, CEO, Koneksa. “We are establishing Data Syndication partnerships as a new form of pre-competitive collaboration that brings together a community around real-time data sharing and analysis throughout our studies to accelerate the validation and adoption of better digital measures.”.

Koneksa首席执行官克里斯·本科（ChrisBenko）表示：“医疗保健界迫切需要更好地验证帕金森病进展的措施，以为药物开发提供信息。”。“我们正在建立数据联合伙伴关系，作为一种新的竞争前合作形式，将整个研究过程中围绕实时数据共享和分析的社区聚集在一起，以加速验证和采用更好的数字措施。”。

“Digital technologies provide an opportunity to quantitatively and objectively assess disease progression and treatment effect in people with Parkinson’s disease,” said Dr. Aubrey Stoch, Head of Translational Medicine, Merck Research Laboratories. “As a founding member of Koneksa’s data syndication community, we are excited to collaborate to further the development of digital measures and advance understanding of this debilitating disease.”.

默克研究实验室转化医学负责人AubreyStoch博士说：“数字技术为定量和客观地评估帕金森病患者的疾病进展和治疗效果提供了机会。”。“作为Koneksa数据联合社区的创始成员，我们很高兴能够合作进一步开发数字测量并增进对这种衰弱疾病的理解。”。

The LEARNS study plans to study disease progression for 12 months in up to 70 people with Parkinson’s disease. The capture of remote measurements from the Koneksa Neuroscience Toolkit, which implements iPhone-based active assessments and passive monitoring using a wrist-worn wearable, provides an opportunity to capture more objective and frequent measures of disease change and impact in the context of daily living and in a more convenient fashion.

LEARNS研究计划对70名帕金森氏病患者进行为期12个月的疾病进展研究。从Koneksa Neuroscience Toolkit中捕获远程测量，该工具包使用手腕佩戴的可穿戴设备实现基于iPhone的主动评估和被动监测，为在日常生活中以更方便的方式捕获更客观和频繁的疾病变化和影响测量提供了机会。

Koneksa announced in February that the first patient was enrolled in the LEARNS study..

Koneksa于2月宣布，第一名患者参加了LEARDS研究。。

The high-precision longitudinal data and in-clinic data from the LEARNS study will guide future development of digital biomarkers of disease progression in Parkinson’s disease. Data syndication gives partners immediate and continuous access to data and results as the study progresses, and access to the study dashboard from Koneksa’s proprietary platform for real-time study monitoring, enabling syndication partners to learn from the study as it progresses..

来自LEARNS研究的高精度纵向数据和临床数据将指导帕金森病疾病进展数字生物标志物的未来发展。随着研究的进展，数据联合使合作伙伴能够立即、持续地访问数据和结果，并可以从Koneksa专有平台访问研究仪表盘，以进行实时研究监测，使联合合作伙伴能够在研究进展中学习。。

For more information about Data Syndication, contact Koneksa at dave.hurry@koneksahealth.com. More information on the LEARNS study is available at clinicaltrials.gov (NCT06219629).

有关数据联合的更多信息，请联系Koneksadave.hurry@koneksahealth.com.有关LEARNS研究的更多信息，请访问clinicaltrials.gov（NCT06219629）。

About Koneksa

关于Koneksa

Koneksa is a healthcare technology company pioneering evidence-based digital biomarkers to accelerate clinical research and guide decision-making in drug development and market strategy. Our evidence-based biomarker solutions enable efficient clinical trial designs to help innovative therapies reach patients faster.

Koneksa是一家医疗保健技术公司，开创了基于证据的数字生物标志物，以加速临床研究并指导药物开发和市场战略的决策。我们基于证据的生物标志物解决方案能够实现有效的临床试验设计，以帮助创新疗法更快地到达患者。

Koneksa aims to revolutionize treatment effect detection in clinical research and improve patient outcomes. Learn more at koneksahealth.com..

Koneksa旨在彻底改变临床研究中的治疗效果检测，并改善患者预后。更多信息，请访问koneksahealth.com。。